Shield Multi Cancer Detection Blood Test

Iron DPC is now offering the Shield blood test from Guardant Health which represents an innovative advancement in cancer screening using a simple blood draw to analyze cell-free DNA for cancer signals.

This test is offered to patients at Iron DPC with commercial or medicare insurance over age 45 (cash rate is about $1,000 and we would prefer the Prenuvo full body MRI if spending that much).

Guardant offers two distinct versions under the Shield platform: the FDA-approved Shield test for colorectal cancer (CRC) screening, and the investigational Shield Multi-Cancer Detection (MCD) test, which is in development and has received FDA Breakthrough Device Designation but is not yet approved or commercially available.This distinction is important for patients and providers: the standard Shield is a validated, guideline-endorsed option specifically for CRC, while the MCD version aims to broaden screening to multiple cancers but remains under evaluation in ongoing studies like the National Cancer Institute's Vanguard trial.

FDA-Approved Shield Test: Colorectal Cancer ScreeningThe Shield test received full FDA approval in July 2024 as the first blood-based primary screening option for colorectal cancer in average-risk adults aged 45 and older. Its performance is based on the large ECLIPSE study (over 20,000 participants) and a subsequent 2025 update with an improved algorithm (Shield V2), which met all primary endpoints in an expanded cohort.

• Overall Sensitivity for CRC: 84% (improved from the original 83% in the initial ECLIPSE publication).

• Specificity: 90% for advanced neoplasia (including CRC and advanced adenomas), meaning a low false-positive rate to reduce unnecessary follow-up colonoscopies.

• Sensitivity by CRC Stage:

  • Stage I (early): 62%

  • Stage II: 100%

  • Stage III: 96%

  • Stage IV (advanced): 100%

• Sensitivity for Advanced Adenomas (precancerous lesions): 13% — a noted limitation, as the test is stronger at detecting actual cancer than preventing it by finding precancers (unlike colonoscopy, which allows removal of polyps).

A positive result requires confirmatory colonoscopy. The test is recommended every 3 years for average-risk individuals and is now included in National Comprehensive Cancer Network (NCCN) guidelines.Shield Multi-Cancer Detection (MCD) Test: Investigational for Multiple CancersThe Shield MCD test is a separate, methylation-based assay designed to screen for multiple cancer types in average-risk adults aged 45+. It received FDA Breakthrough Device Designation in June 2025, accelerating development due to its potential impact. It is not FDA-approved and remains investigational, with data primarily from case-control studies presented at conferences like ASCO 2025.Key performance highlights (from 2025 clinical validation data):

• Overall Specificity: 98.5–98.6% (very high, minimizing false positives across cancer-free individuals).

• Overall Sensitivity: Varies by analysis — 75% across eight aggressive cancers (bladder, colorectal, esophageal-gastric, liver, lung, ovarian, pancreas); 60% in broader cohorts including 10 tumor types.

• Cancer Signal Origin (CSO) Accuracy: 89–92% (helps predict the likely tissue source of a positive signal to guide follow-up tests like imaging or biopsies).

• Sensitivities are stage-dependent, often higher for advanced disease (III/IV) where more tumor DNA circulates.

The test focuses on cancers with high unmet needs. Here's a breakdown from key 2025 data (primarily the eight-cancer cohort with 75% overall sensitivity and 98.6% specificity; ranges from broader 10-cancer evaluations noted where relevant):

Cancer Type	Overall Sensitivity	Stage I/II Sensitivity	Stage III/IV Sensitivity	Notes
Bladder	62%	~44%	100%	Solid for advanced.
Breast	~45% (in some cohorts)	Low (~17%)	High (~88%)	Not primary focus.
Colorectal	83%	~53%	100%	Aligns with approved CRC version.
Esophageal-Gastric	96%	100%	~95%	Among the highest.
Hepatocellular (Liver)	94%	100%	~92%	Excellent early detection.
Lung	67%	~41%	93%	Good for aggressive types.
Ovarian	70%	80%	~67%	Stronger in early stages.
Pancreas	68%	50%	96%	Focus on lethal cancer.
Prostate	21% (in 10-cancer data)	~3%	~41%	Lowest; challenging due to low DNA shedding.

Additional cancers evaluated (e.g., endometrial ~38%, head & neck ~80%, kidney ~34%) show variable results, as the test is optimized for core types.Key Takeaways for Patients and Providers

• The FDA-approved Shield offers a convenient, non-invasive CRC screening alternative with strong performance for detecting cancer (especially later stages) and good specificity, though it misses many precancers.

• The Shield MCD shows exciting promise as a "one-blood-draw" approach for multiple hard-to-screen cancers, with exceptional specificity and meaningful sensitivity for aggressive types — but it's not ready for routine use yet. Prospective trials will clarify real-world performance in screening populations.

• Neither replaces established single-cancer screens (e.g., mammograms, colonoscopies). Positive MCD results would prompt targeted diagnostics based on predicted origin.

As research evolves, blood-based tests like these could transform early detection, especially for cancers without current routine screening. Always discuss options with your healthcare provider based on individual risk factors. If you're interested please discuss with your Iron DPC primary care provider.